Plasma cell disorders in HIV-infected patients: Epidemiology and molecular mechanisms

被引：31
作者：
Coker W.J. [1 ]
Jeter A. [1 ]
Schade H. [1 ]
Kang Y. [1 ]
机构：
[1] Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, 29425
来源：
Biomarker Research | / 1卷 / 1期
基金：
美国国家卫生研究院;
关键词：
AIDS; Epidemiology; Gammopathy; Hematopoietic stem cell transplantation; HIV; Molecular mechanism; Multiple myeloma; Outcome; Treatment;
D O I：
10.1186/2050-7771-1-8
中图分类号：
学科分类号：
摘要：
Highly active antiretroviral therapy (HAART) has significantly improved the outcome and survival of human immunodeficiency virus (HIV)-infected patients. Subsequently, long-term morbidities including cancer have become of major public health and clinical interest for this patient population. Plasma cell disorders occur at higher incidence in HIV-infected patients; however, the molecular mechanisms driving the plasma cell disease process and the optimal management for these patients remain to be defined. This article provides an up-to-date review of the characteristics and management of HIV-infected patients with plasma cell disorders. We first present 3 cases of plasma cell disorders in HIV-infected patients, ranging from polyclonal hypergammaglobulinemia to symptomatic multiple myeloma. We then discuss the epidemiology, clinical presentation, and management of each of these plasma cell disorders, with an emphasis on the molecular events underlying the progression of plasma cell diseases from monoclonal gammopathy to symptomatic multiple myeloma. We propose a three-step hypothesis for the development of multiple myeloma. Finally, we discuss the use of high dose chemotherapy and autologous hematopoietic stem cell transplantation in the treatment of HIV-infected patients with multiple myeloma. Our review includes the care of HIV-infected patients with plasma cell disorders in the current era of HAART and novel agents available for the treatment of multiple myeloma. © 2013 Coker et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 108 条
[1]  
Couzigou C., Semaille C., Le Strat Y., Pinget R., Pillonel J., Lot F., Cazein F., Vittecoq D., Desenclos J.C., Differential improvement in survival among patients with AIDS after the introduction of HAART, AIDS Care, 19, 4, pp. 523-531, (2007)
[2]  
Cheung M.C., Pantanowitz L., Dezube B.J., AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy, Oncologist, 10, 6, pp. 412-426, (2005)
[3]  
Dezube B.J., Aboulafia D.M., Pantanowitz L., Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma, AIDS Read, 14, 7, pp. 372-374, (2004)
[4]  
Becker N., Epidemiology of multiple myeloma, Recent Results Cancer Res, 183, pp. 25-35, (2011)
[5]  
Konstantinopoulos P.A., Pantanowitz L., Dezube B.J., Higher prevalence of monoclonal gammopathy of undetermined significance in African Americans than whites-the unknown role of underlying HIV infection, J Natl Med Assoc, 98, 11, pp. 1860-1861, (2006)
[6]  
Fiorino A.S., Atac B., Paraproteinemia, plasmacytoma, myeloma and HIV infection, Leukemia, 11, 12, pp. 2150-2156, (1997)
[7]  
Rajkumar S.V., Kyle R.A., Multiple myeloma: diagnosis and treatment, Mayo Clin Proc, 80, 10, pp. 1371-1382, (2005)
[8]  
Kyle R.A., Durie B.G., Rajkumar S.V., Landgren O., Blade J., Merlini G., Kroger N., Einsele H., Vesole D.H., Dimopoulos M., Et al., Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, Leukemia, 24, 6, pp. 1121-1127, (2010)
[9]  
Shirai A., Cosentino M., Leitman-Klinman S.F., Klinman D.M., Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation, J Clin Invest, 89, 2, pp. 561-566, (1992)
[10]  
De Milito A., Nilsson A., Titanji K., Thorstensson R., Reizenstein E., Narita M., Grutzmeier S., Sonnerborg A., Chiodi F., Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection, Blood, 103, 6, pp. 2180-2186, (2004)
12345678910